Blue

Ali Chappell, PhD, RD, Co-Founder and CEO of Lilli Health, shares how she transformed her experience with PCOS into a data-driven nutrition and wellness company offering services and app to have “a dietitian in your pocket.”


How a PCOS Diagnosis Fueled One Founder’s Mission to Disrupt Women’s Health

The shortage of anti-obesity medications is sending patients to gray markets while healthcare innovators look for longer-term solutions beyond of GLP-1s.

How Entrepreneurs are Looking Beyond GLP-1s for Obesity Innovations

Two NYC-based startups, GenKardia and Sidereal Therapeutics, have each won a $250,000 XSeed Award to support moving promising preclinical research of novel therapies for kidney and heart disease forward toward commercialization.

$250K XSeed Awards Granted to Minority- and Women-Led Startups Advancing New Drugs 

Cure® Announces 2025 XSeed Award Winners, Advancing Minority- and Women-Led Life Science Startups in New York City

Sidereal Therapeutics is developing a potential first-in-class biologic to prevent acute kidney injury from progressing to chronic disease by targeting iron overload at its source.

Novel Biologic Aims to Stop Kidney Damage Before it Turns Chronic

Big drugmakers and direct-to-consumer clinics are expanding obesity care with new GLP-1s, cheaper self-pay options and new therapies that may transform this rapidly evolving market.

Obesity Drug Market Charts New Course for Patients, Investors image

Obesity Drug Market Charts New Course for Patients, Investors

Non-invasive devices unveiled at CES 2025 aim to transform metabolic disease prevention and management.

Breaking the Blood Barrier in Metabolic Care at CES 2025

Expert panel explores patient experiences with GLP-1 and the future of obesity treatments at Biotech Showcase 2025.

Reality Check: Doctors Challenge GLP-1 "Magic Drug" Narrative 

To understand GLP-1s use for weight loss, CURE surveyed current and former patients about their attitudes and experience.

Patients Use GLP-1 Drugs for Weight Loss, Gaining Benefits

thumbnail_GLP1RA_patients_survey_GTY2025837217

Patients' Use GLP-1 Drugs for Weight Loss, Benefit Gains

To understand current prescribing practices for off-label use of GLP-1Rs, CURE surveyed physicians across the specialties of gastroenterology, addiction medicine, cardiology, neurology and orthopedics.

Specialty Physicians on Using GLP-1 Drugs Off Label 

The successful treatment of patients with IBD, such as ulcerative colitis or Crohn's disease, might be transformed by Insilico’s ISM5411.



AI-Designed Therapy for Inflammatory Bowel Disease Advances

Lexeo Therapeutics is developing pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease.

Lexeo Therapeutics: Revolutionizing Genetic Medicine for Cardiovascular and Neurodegenerative Diseases 

The U.S. government's ARPA-H launched HEROS to make preventing illness as rewarding as delivery acute care for providers, creating more equitable, health outcomes for all Americans.

thumbnail-arpah-heroes-program-preventive

ARPA-H's HEROES Program Accelerates Preventive Health Innovations

Longevity drugs to head off diseases of aging and extend healthy lifespans are tantalizingly close, yet translating basic science discoveries to drugs still have hurdles to pass. James Peyer, PhD, CEO and Founder of Cambrian Bio talks about pursuing treatments that extend human healthspans.

thumbnail_cambrian_Bios_Drug_Strategy_age-related

Cambrian Bio’s Drug Strategy for Age-Related Diseases

Explore the candid opinions of endocrinologists on GLP-1 drugs like Ozempic and Mounjaro. Uncover their thoughts on efficacy, patient satisfaction and the future landscape of these groundbreaking treatments in our white paper.

White Paper GLP-1

What Doctors Really Think of GLP-1 Medications

Cure® Unveils US Biotech Industry Benchmark Report 2024: Dark Days of 2023 are Over

Maliha Ahmad, MD, an innovator and leader in preventive care for liver disease, believes that re-thinking diagnostics and interventions could change liver health for millions.

The Passion of a Liver Doctor -- Maliha Ahmad MD

Fighting Liver Disease with Detection, AI and Novel Therapies 

Scientific innovations can come from our most personal experiences. For Ed Damiano, PhD, the co-founder of Beta Bionics, his transformational invention began with his son’s diagnosis of type 1 diabetes and an unwavering determination to find a better way to manage the condition.

Bionic Pancreas Transforms Care for People with Type 1 Diabetes

Insights

A conversation with Ed Damiano, PhD, Founder and Executive Chair of the medical device company Beta Bionics.

Cure Tuesday Talks banner image Ed Damiano

A Father Who is Changing the Landscape for Patients with Type 1 Diabetes

Events

Become a member of Cure and help shape the future of healthcare.

Join our community

Regular

345 Park Avenue South

Xchange Challenge

All floors are lab-ready and cabled for digital health.

Community

Apply for Membership

Residents

Leadership

Staff

Neighborhood

Be part of *Cure.*

Orange

Where scientists, entrepreneurs and visionaries converge.

Campus

Ecosystem

Event Spaces

Gallery

Networking hub

Space Availability

A place to *Succeed.*

Green

Joe Wilson How Life Sciences Companies Use AI to Target Investors Mega Menu Image 

Critical Discussions Advancing Healthcare

Event Inquiry

Past Events

Speakers

Tuesday Talks

Cure *Events.*

Magenta

Cure Clips

Tuesday Talks Series

Cure *Tuesday Talks*

Award Finalists to be announced soon!

Partnerships and Sponsorships

Women in Science

XSeed Award

Connect with *Opportunity.*

Network

Cure Insights Article A Bionic Pancreas that will Help Parents Sleep More Peacefully image for Cure Insights Mega Menu.  Image credit Cottonbro Studio.

Metabolic Diseases

Insights

Events

Recommended Topics

Join our community